Ventyx Biosciences
Henrik Sonnergren currently serves as Senior Medical Director of Clinical Development at Ventyx Biosciences since May 2024, focusing on strategic planning and obesity among other skills. Prior to this role, Henrik held the position of Global Medical Director of Clinical Research in Inflammation at Amgen from October 2021 to May 2024, emphasizing global management and Good Clinical Practice (GCP). Additionally, positions at Novo Nordisk, Eli Lilly and Company, and Janssen Inc. involved senior roles in medical management and clinical research, particularly in immunology and psoriasis. Henrik's academic background includes a Doctor of Philosophy (PhD) in Dermatology and a Doctor of Medicine (MD) from the University of Gothenburg, completed between 2008 and 2015.
This person is not in any teams
This person is not in any offices
Ventyx Biosciences
1 followers
Ventyx Biosciences is a biotechnology company with a diverse portfolio of best-in-class highly differentiated clinical and pre-clinical stage programs focused on high-value targets. Ventyx now includes combined assets from three separate companies: Oppilan Pharma, targeting S1P1R, Zomagen Biosciences, targeting NLRP3 and the inflammasome, and Ventyx Biosciences, targeting TYK2.